Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

NCT05762640 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Haemophagocytic Lymphohistiocytosis

Interventions

DRUG: Ruxolitinib

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]